S&P 500
(0.80%) 5 058.42 points
Dow Jones
(0.69%) 38 167 points
Nasdaq
(1.40%) 15 823 points
Oil
(0.01%) $79.01
Gas
(5.49%) $2.04
Gold
(0.05%) $2 312.10
Silver
(0.46%) $26.87
Platinum
(0.79%) $962.45
USD/EUR
(-0.06%) $0.932
USD/NOK
(-0.30%) $11.00
USD/GBP
(-0.08%) $0.798
USD/RUB
(-1.33%) $92.02

Realaus laiko atnaujinimai Abbott Laboratories [ABT]

Birža: NYSE Sektorius: Healthcare Pramonė: Medical - Devices
Atnaujinta2 geg. 2024 @ 22:42

-0.52% $ 105.74

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:42):

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...

Stats
Šios dienos apimtis 2.39M
Vidutinė apimtis 5.67M
Rinkos kapitalizacija 183.48B
EPS $0 ( 2024-04-17 )
Kita pelno data ( $1.100 ) 2024-07-18
Last Dividend $0.550 ( 2024-04-12 )
Next Dividend $0 ( N/A )
P/E 32.94
ATR14 $0.0470 (0.04%)
Insider Trading
Date Person Action Amount type
2024-04-26 Stratton John G Buy 1 866 Common shares without par value
2024-04-26 Starks Daniel J Buy 1 866 Common shares without par value
2024-04-26 Starks Daniel J Buy 5 277 Option (right to buy)
2024-04-26 Roman Michael F Buy 1 866 Common shares without par value
2024-04-26 O'grady Michael Buy 4 404 Option (right to buy)
INSIDER POWER
55.29
Last 99 transactions
Buy: 1 141 010 | Sell: 385 716

Tūris Koreliacija

Ilgas: -0.17 (neutral)
Trumpas: -0.81 (strong negative)
Signal:(20.691) Be Aware. Possible trading coming up! (swing)

Abbott Laboratories Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ULE0.948
FXE0.947
UDN0.941
EWN0.937
BWX0.936
DRI0.935
NERD0.934
LEMB0.932
EMLC0.932
BYM0.931
10 Labiausiai neigiamai susiję koreliacijos
EUO-0.946
UUP-0.923
TNK-0.916
USDU-0.909
DEX-0.902
TYO-0.893
PST-0.892
TBX-0.886
TMV-0.883
MIE-0.883

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Abbott Laboratories Koreliacija - Valiuta/Žaliavos

The country flag 0.55
( weak )
The country flag 0.37
( neutral )
The country flag 0.00
( neutral )
The country flag 0.53
( weak )
The country flag -0.75
( moderate negative )
The country flag 0.27
( neutral )

Abbott Laboratories Finansinės ataskaitos

Annual 2023
Pajamos: $40.11B
Bruto pelnas: $22.13B (55.18 %)
EPS: $3.30
FY 2023
Pajamos: $40.11B
Bruto pelnas: $22.13B (55.18 %)
EPS: $3.30
FY 2022
Pajamos: $43.65B
Bruto pelnas: $24.51B (56.15 %)
EPS: $3.94
FY 2021
Pajamos: $43.08B
Bruto pelnas: $24.54B (56.97 %)
EPS: $3.99

Financial Reports:

No articles found.

Abbott Laboratories Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.470
(N/A)
$0.470
(N/A)
$0.510
(N/A)
$0.510
(N/A)
$0.510
(N/A)
$0.510
(N/A)
$0.550
(N/A)
$0.550
(N/A)
$0
(N/A)
$0
(N/A)

Abbott Laboratories Dividend Information - Dividend Knight

Dividend Sustainability Score: 4.81 - low (59.75%) | Divividend Growth Potential Score: 6.17 - Stable (23.43%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.00589 1983-01-11
Last Dividend $0.550 2024-04-12
Next Dividend $0 N/A
Payout Date 2024-05-15
Next Payout Date N/A
# dividends 166 --
Total Paid Out $25.20 --
Avg. Dividend % Per Year 1.43% --
Score 4.72 --
Div. Sustainability Score 4.81
Div.Growth Potential Score 6.17
Div. Directional Score 5.49 --
Next Divdend (Est)
(2024-07-02)
$0.557 Estimate 74.91 %
Dividend Stability
1.00 Excellent
Dividend Score
4.72
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
1983 $0.0269 2.59%
1984 $0.0323 2.50%
1985 $0.0379 3.32%
1986 $0.0452 2.37%
1987 $0.0398 1.49%
1988 $0.0644 2.36%
1989 $0.0756 2.82%
1990 $0.0904 2.32%
1991 $0.108 2.22%
1992 $0.129 1.71%
1993 $0.148 2.17%
1994 $0.166 2.57%
1995 $0.184 2.50%
1996 $0.209 2.23%
1997 $0.296 2.62%
1998 $0.263 1.73%
1999 $0.296 1.35%
2000 $0.332 2.11%
2001 $0.368 1.70%
2002 $0.409 1.63%
2003 $0.435 2.42%
2004 $0.477 2.27%
2005 $0.521 2.33%
2006 $0.558 2.94%
2007 $0.610 2.60%
2008 $0.675 2.52%
2009 $0.749 2.91%
2010 $0.825 3.16%
2011 $0.901 3.93%
2012 $0.965 3.55%
2013 $0.560 1.75%
2014 $0.880 2.30%
2015 $0.960 2.14%
2016 $1.040 2.42%
2017 $1.060 2.71%
2018 $1.120 1.91%
2019 $1.280 1.84%
2020 $1.440 1.66%
2021 $1.800 1.65%
2022 $1.880 1.35%
2023 $2.04 1.86%
2024 $1.100 1.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOMA Dividend Knight 2023-06-30 Quarterly 2 5.23% 8.53
PVL Dividend King 2023-11-15 Monthly 14 9.37% 8.50
JQC Dividend Royal 2023-11-14 Monthly 22 6.56% 8.50
NCV Dividend Royal 2024-02-09 Monthly 22 7.68% 8.50
SBR Dividend Royal 2023-11-14 Monthly 38 7.74% 8.50
SCM Dividend King 2023-12-15 Monthly 13 7.08% 8.50
MTR Dividend Diamond 2023-10-30 Monthly 39 10.10% 8.50
PDI Dividend Royal 2023-11-10 Monthly 13 7.86% 8.50
SJT Dividend Royal 2023-11-29 Monthly 39 12.52% 8.50
ORC Dividend Royal 2023-11-29 Monthly 12 9.23% 8.50

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1401.5007.2110.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.1481.5009.4710.00[0.1 - 1]
payoutRatioTTM0.474-1.0005.26-5.26[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM10.861.0007.097.09[3 - 30]
operatingCashFlowPerShareTTM3.532.008.8210.00[0 - 30]
freeCashFlowPerShareTTM2.482.008.7610.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.5411.0004.314.31[0.2 - 0.8]
operatingProfitMarginTTM0.1671.0008.658.65[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.81

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM32.741.0006.790[1 - 100]
returnOnEquityTTM0.1482.509.6610.00[0.1 - 1.5]
freeCashFlowPerShareTTM2.482.009.1710.00[0 - 30]
dividendYielPercentageTTM1.9951.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM3.532.008.8210.00[0 - 30]
payoutRatioTTM0.4741.5005.26-5.26[0 - 1]
pegRatioTTM0.3321.500-1.1220[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1521.0008.710[0.1 - 0.5]
Total Score6.17

Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.